10 Nov 2015 08:30 a.m. - 02:00 p.m.

Download Stephen Thau's Presentation Materials

Download Jaclyn Liu's Presentation Materials

Israeli companies that are not public face many issues – How can we obtain the capital we need to grow? Should we consider a strategic investment or distribution agreement with a larger company? How should we communicate with institutional investors and the public generally? This program will help you answer those questions. While the focus will be on med-tech, biotech, health care and other life science companies, the issues they face are similar to the issues confronting all private Israeli technology companies.

The program will feature the following speakers:

• Dr. Hadar Ron, Managing Partner, Israel HealthCare Ventures
• Daniel H. Burch, Chief Executive Officer, MacKenzie Partners, Inc.
• Paul Schulman, Executive Vice President, MacKenzie Partners, Inc.
• Gera Strommer, Chairman & CEO, NewPace Ltd, Former CEO, MediGuide, Inc.
• Maya Liquornik, Partner, Meitar Liquornik Geva Leshem Tal, Law Offices
• Shiri Shaham, Partner, Yigal Arnon & Co.
• Nir Dash, Partner, Herzog Fox & Neeman
• Gene Kleinhendler, Partner, Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.
• Stephen B. Thau, Partner, Morrison & Foerster
• Jaclyn Liu, Partner, Morrison & Foerster
• Bruce Mann, Senior Counsel, Morrison & Foerster

Questions the speakers will focus on include:

• How to approach venture capitalists and what do they consider in investing in life science companies?
• Who are the institutional investors, how do you establish relations with them, and how do they decide how to invest or vote?
• What are the pitfalls of seeking investment from strategic investors?
• Are the Tel Aviv Stock Exchange, Euronext, AIM or other markets alternatives to a U.S. IPO that should be considered?
• How should you prepare for a successful NASDAQ of NYSE IPO?
• Is a sale or joint venture with a public company a viable alternative to an IPO?